nodes	percent_of_prediction	percent_of_DWPC	metapath
Flecainide—CYP2C9—Sorafenib—liver cancer	0.122	0.405	CbGbCtD
Flecainide—CYP2D6—Sorafenib—liver cancer	0.112	0.37	CbGbCtD
Flecainide—CYP2D6—Doxorubicin—liver cancer	0.0677	0.225	CbGbCtD
Flecainide—Dysphonia—Sorafenib—liver cancer	0.0135	0.0201	CcSEcCtD
Flecainide—Neuropathy—Sorafenib—liver cancer	0.0104	0.0155	CcSEcCtD
Flecainide—Gynaecomastia—Sorafenib—liver cancer	0.00995	0.0148	CcSEcCtD
Flecainide—Hepatic function abnormal—Sorafenib—liver cancer	0.00924	0.0137	CcSEcCtD
Flecainide—Hepatic failure—Sorafenib—liver cancer	0.00898	0.0133	CcSEcCtD
Flecainide—Cardiac failure congestive—Sorafenib—liver cancer	0.0089	0.0132	CcSEcCtD
Flecainide—Dermatitis exfoliative—Sorafenib—liver cancer	0.00855	0.0127	CcSEcCtD
Flecainide—Erectile dysfunction—Sorafenib—liver cancer	0.00643	0.00954	CcSEcCtD
Flecainide—Parosmia—Epirubicin—liver cancer	0.00634	0.00941	CcSEcCtD
Flecainide—Pneumonia—Sorafenib—liver cancer	0.00626	0.00929	CcSEcCtD
Flecainide—Renal failure—Sorafenib—liver cancer	0.00612	0.00908	CcSEcCtD
Flecainide—Neuropathy peripheral—Sorafenib—liver cancer	0.0061	0.00905	CcSEcCtD
Flecainide—Jaundice—Sorafenib—liver cancer	0.00606	0.009	CcSEcCtD
Flecainide—Parosmia—Doxorubicin—liver cancer	0.00586	0.0087	CcSEcCtD
Flecainide—Nystagmus—Epirubicin—liver cancer	0.00575	0.00854	CcSEcCtD
Flecainide—Scotoma—Epirubicin—liver cancer	0.00541	0.00803	CcSEcCtD
Flecainide—Nystagmus—Doxorubicin—liver cancer	0.00532	0.0079	CcSEcCtD
Flecainide—Tinnitus—Sorafenib—liver cancer	0.00521	0.00773	CcSEcCtD
Flecainide—Flushing—Sorafenib—liver cancer	0.00518	0.00769	CcSEcCtD
Flecainide—Ageusia—Epirubicin—liver cancer	0.00507	0.00753	CcSEcCtD
Flecainide—Immune system disorder—Sorafenib—liver cancer	0.00504	0.00749	CcSEcCtD
Flecainide—Scotoma—Doxorubicin—liver cancer	0.00501	0.00743	CcSEcCtD
Flecainide—Dysphonia—Epirubicin—liver cancer	0.005	0.00742	CcSEcCtD
Flecainide—Alopecia—Sorafenib—liver cancer	0.00493	0.00733	CcSEcCtD
Flecainide—Blood disorder—Epirubicin—liver cancer	0.00492	0.00731	CcSEcCtD
Flecainide—Dysgeusia—Sorafenib—liver cancer	0.00476	0.00707	CcSEcCtD
Flecainide—Ageusia—Doxorubicin—liver cancer	0.00469	0.00697	CcSEcCtD
Flecainide—Dysphonia—Doxorubicin—liver cancer	0.00462	0.00686	CcSEcCtD
Flecainide—Blood disorder—Doxorubicin—liver cancer	0.00455	0.00676	CcSEcCtD
Flecainide—Skin discolouration—Epirubicin—liver cancer	0.00455	0.00676	CcSEcCtD
Flecainide—Dyskinesia—Epirubicin—liver cancer	0.00437	0.00649	CcSEcCtD
Flecainide—Syncope—Sorafenib—liver cancer	0.00436	0.00647	CcSEcCtD
Flecainide—Leukopenia—Sorafenib—liver cancer	0.00435	0.00646	CcSEcCtD
Flecainide—Loss of consciousness—Sorafenib—liver cancer	0.00427	0.00634	CcSEcCtD
Flecainide—Cough—Sorafenib—liver cancer	0.00424	0.0063	CcSEcCtD
Flecainide—Atrioventricular block—Epirubicin—liver cancer	0.00424	0.00629	CcSEcCtD
Flecainide—Skin discolouration—Doxorubicin—liver cancer	0.00421	0.00625	CcSEcCtD
Flecainide—Hypertension—Sorafenib—liver cancer	0.0042	0.00623	CcSEcCtD
Flecainide—Myalgia—Sorafenib—liver cancer	0.00414	0.00614	CcSEcCtD
Flecainide—Arthralgia—Sorafenib—liver cancer	0.00414	0.00614	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00411	0.0061	CcSEcCtD
Flecainide—Ventricular tachycardia—Epirubicin—liver cancer	0.00411	0.0061	CcSEcCtD
Flecainide—Abnormal dreams—Epirubicin—liver cancer	0.00406	0.00603	CcSEcCtD
Flecainide—Dry mouth—Sorafenib—liver cancer	0.00405	0.00601	CcSEcCtD
Flecainide—Dyskinesia—Doxorubicin—liver cancer	0.00405	0.00601	CcSEcCtD
Flecainide—Atrioventricular block—Doxorubicin—liver cancer	0.00392	0.00582	CcSEcCtD
Flecainide—Shock—Sorafenib—liver cancer	0.0039	0.0058	CcSEcCtD
Flecainide—Nervous system disorder—Sorafenib—liver cancer	0.00389	0.00578	CcSEcCtD
Flecainide—Thrombocytopenia—Sorafenib—liver cancer	0.00388	0.00577	CcSEcCtD
Flecainide—Neuropathy—Epirubicin—liver cancer	0.00386	0.00573	CcSEcCtD
Flecainide—Skin disorder—Sorafenib—liver cancer	0.00385	0.00572	CcSEcCtD
Flecainide—Ventricular tachycardia—Doxorubicin—liver cancer	0.0038	0.00565	CcSEcCtD
Flecainide—Anorexia—Sorafenib—liver cancer	0.00378	0.00562	CcSEcCtD
Flecainide—Abnormal dreams—Doxorubicin—liver cancer	0.00376	0.00558	CcSEcCtD
Flecainide—Coma—Epirubicin—liver cancer	0.00376	0.00558	CcSEcCtD
Flecainide—Pulmonary oedema—Epirubicin—liver cancer	0.00366	0.00543	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00361	0.00537	CcSEcCtD
Flecainide—Neuropathy—Doxorubicin—liver cancer	0.00357	0.0053	CcSEcCtD
Flecainide—Dyspnoea—Sorafenib—liver cancer	0.00354	0.00525	CcSEcCtD
Flecainide—Dyspepsia—Sorafenib—liver cancer	0.00349	0.00519	CcSEcCtD
Flecainide—Coma—Doxorubicin—liver cancer	0.00347	0.00516	CcSEcCtD
Flecainide—Decreased appetite—Sorafenib—liver cancer	0.00345	0.00512	CcSEcCtD
Flecainide—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.00343	0.00509	CcSEcCtD
Flecainide—Gastrointestinal disorder—Sorafenib—liver cancer	0.00343	0.00509	CcSEcCtD
Flecainide—Fatigue—Sorafenib—liver cancer	0.00342	0.00508	CcSEcCtD
Flecainide—Hepatic function abnormal—Epirubicin—liver cancer	0.00341	0.00507	CcSEcCtD
Flecainide—Pain—Sorafenib—liver cancer	0.00339	0.00504	CcSEcCtD
Flecainide—Constipation—Sorafenib—liver cancer	0.00339	0.00504	CcSEcCtD
Flecainide—Pulmonary oedema—Doxorubicin—liver cancer	0.00338	0.00503	CcSEcCtD
Flecainide—Hepatic failure—Epirubicin—liver cancer	0.00332	0.00493	CcSEcCtD
Flecainide—Eye pain—Epirubicin—liver cancer	0.0033	0.00491	CcSEcCtD
Flecainide—Cardiac failure congestive—Epirubicin—liver cancer	0.00329	0.00488	CcSEcCtD
Flecainide—Gastrointestinal pain—Sorafenib—liver cancer	0.00324	0.00482	CcSEcCtD
Flecainide—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.00317	0.00471	CcSEcCtD
Flecainide—Dermatitis exfoliative—Epirubicin—liver cancer	0.00316	0.00469	CcSEcCtD
Flecainide—Hepatic function abnormal—Doxorubicin—liver cancer	0.00316	0.00469	CcSEcCtD
Flecainide—Urticaria—Sorafenib—liver cancer	0.00315	0.00468	CcSEcCtD
Flecainide—Abdominal pain—Sorafenib—liver cancer	0.00314	0.00466	CcSEcCtD
Flecainide—Body temperature increased—Sorafenib—liver cancer	0.00314	0.00466	CcSEcCtD
Flecainide—Hepatic failure—Doxorubicin—liver cancer	0.00307	0.00456	CcSEcCtD
Flecainide—Eye pain—Doxorubicin—liver cancer	0.00306	0.00454	CcSEcCtD
Flecainide—Cardiac failure congestive—Doxorubicin—liver cancer	0.00304	0.00452	CcSEcCtD
Flecainide—Diplopia—Epirubicin—liver cancer	0.00298	0.00443	CcSEcCtD
Flecainide—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.00298	0.00443	CcSEcCtD
Flecainide—Dermatitis exfoliative—Doxorubicin—liver cancer	0.00293	0.00434	CcSEcCtD
Flecainide—Asthenia—Sorafenib—liver cancer	0.00285	0.00423	CcSEcCtD
Flecainide—Cardiac arrest—Epirubicin—liver cancer	0.00284	0.00421	CcSEcCtD
Flecainide—Pruritus—Sorafenib—liver cancer	0.00281	0.00417	CcSEcCtD
Flecainide—Ataxia—Epirubicin—liver cancer	0.00281	0.00416	CcSEcCtD
Flecainide—Diplopia—Doxorubicin—liver cancer	0.00276	0.0041	CcSEcCtD
Flecainide—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.00276	0.0041	CcSEcCtD
Flecainide—Diarrhoea—Sorafenib—liver cancer	0.00271	0.00403	CcSEcCtD
Flecainide—Cardiac arrest—Doxorubicin—liver cancer	0.00262	0.0039	CcSEcCtD
Flecainide—Dizziness—Sorafenib—liver cancer	0.00262	0.0039	CcSEcCtD
Flecainide—Ataxia—Doxorubicin—liver cancer	0.0026	0.00385	CcSEcCtD
Flecainide—Vomiting—Sorafenib—liver cancer	0.00252	0.00375	CcSEcCtD
Flecainide—Angina pectoris—Epirubicin—liver cancer	0.00251	0.00373	CcSEcCtD
Flecainide—Rash—Sorafenib—liver cancer	0.0025	0.00371	CcSEcCtD
Flecainide—Dermatitis—Sorafenib—liver cancer	0.0025	0.00371	CcSEcCtD
Flecainide—Headache—Sorafenib—liver cancer	0.00249	0.00369	CcSEcCtD
Flecainide—Dysuria—Epirubicin—liver cancer	0.00241	0.00358	CcSEcCtD
Flecainide—Nausea—Sorafenib—liver cancer	0.00236	0.0035	CcSEcCtD
Flecainide—Photosensitivity reaction—Epirubicin—liver cancer	0.00235	0.00349	CcSEcCtD
Flecainide—Hyperglycaemia—Epirubicin—liver cancer	0.00233	0.00345	CcSEcCtD
Flecainide—Angina pectoris—Doxorubicin—liver cancer	0.00232	0.00345	CcSEcCtD
Flecainide—Pneumonia—Epirubicin—liver cancer	0.00231	0.00343	CcSEcCtD
Flecainide—Renal failure—Epirubicin—liver cancer	0.00226	0.00336	CcSEcCtD
Flecainide—Neuropathy peripheral—Epirubicin—liver cancer	0.00225	0.00335	CcSEcCtD
Flecainide—Jaundice—Epirubicin—liver cancer	0.00224	0.00333	CcSEcCtD
Flecainide—Dysuria—Doxorubicin—liver cancer	0.00223	0.00331	CcSEcCtD
Flecainide—Haematuria—Epirubicin—liver cancer	0.00219	0.00325	CcSEcCtD
Flecainide—Photosensitivity reaction—Doxorubicin—liver cancer	0.00218	0.00323	CcSEcCtD
Flecainide—Hyperglycaemia—Doxorubicin—liver cancer	0.00215	0.0032	CcSEcCtD
Flecainide—Agranulocytosis—Epirubicin—liver cancer	0.00215	0.00319	CcSEcCtD
Flecainide—Pneumonia—Doxorubicin—liver cancer	0.00214	0.00318	CcSEcCtD
Flecainide—Bradycardia—Epirubicin—liver cancer	0.0021	0.00312	CcSEcCtD
Flecainide—Renal failure—Doxorubicin—liver cancer	0.00209	0.0031	CcSEcCtD
Flecainide—Neuropathy peripheral—Doxorubicin—liver cancer	0.00209	0.0031	CcSEcCtD
Flecainide—Jaundice—Doxorubicin—liver cancer	0.00207	0.00308	CcSEcCtD
Flecainide—Hypoaesthesia—Epirubicin—liver cancer	0.00205	0.00305	CcSEcCtD
Flecainide—Haematuria—Doxorubicin—liver cancer	0.00203	0.00301	CcSEcCtD
Flecainide—Visual impairment—Epirubicin—liver cancer	0.00199	0.00295	CcSEcCtD
Flecainide—Agranulocytosis—Doxorubicin—liver cancer	0.00199	0.00295	CcSEcCtD
Flecainide—Bradycardia—Doxorubicin—liver cancer	0.00194	0.00289	CcSEcCtD
Flecainide—Eye disorder—Epirubicin—liver cancer	0.00193	0.00286	CcSEcCtD
Flecainide—Tinnitus—Epirubicin—liver cancer	0.00192	0.00286	CcSEcCtD
Flecainide—Flushing—Epirubicin—liver cancer	0.00192	0.00284	CcSEcCtD
Flecainide—Hypoaesthesia—Doxorubicin—liver cancer	0.0019	0.00282	CcSEcCtD
Flecainide—Immune system disorder—Epirubicin—liver cancer	0.00186	0.00277	CcSEcCtD
Flecainide—Visual impairment—Doxorubicin—liver cancer	0.00184	0.00273	CcSEcCtD
Flecainide—Alopecia—Epirubicin—liver cancer	0.00182	0.00271	CcSEcCtD
Flecainide—Eye disorder—Doxorubicin—liver cancer	0.00178	0.00265	CcSEcCtD
Flecainide—Tinnitus—Doxorubicin—liver cancer	0.00178	0.00264	CcSEcCtD
Flecainide—Flushing—Doxorubicin—liver cancer	0.00177	0.00263	CcSEcCtD
Flecainide—Flatulence—Epirubicin—liver cancer	0.00177	0.00263	CcSEcCtD
Flecainide—Tension—Epirubicin—liver cancer	0.00176	0.00262	CcSEcCtD
Flecainide—Dysgeusia—Epirubicin—liver cancer	0.00176	0.00261	CcSEcCtD
Flecainide—Nervousness—Epirubicin—liver cancer	0.00174	0.00259	CcSEcCtD
Flecainide—Immune system disorder—Doxorubicin—liver cancer	0.00172	0.00256	CcSEcCtD
Flecainide—Vision blurred—Epirubicin—liver cancer	0.00169	0.00251	CcSEcCtD
Flecainide—Alopecia—Doxorubicin—liver cancer	0.00169	0.00251	CcSEcCtD
Flecainide—Ill-defined disorder—Epirubicin—liver cancer	0.00167	0.00247	CcSEcCtD
Flecainide—Flatulence—Doxorubicin—liver cancer	0.00164	0.00243	CcSEcCtD
Flecainide—Tension—Doxorubicin—liver cancer	0.00163	0.00242	CcSEcCtD
Flecainide—Dysgeusia—Doxorubicin—liver cancer	0.00163	0.00242	CcSEcCtD
Flecainide—Malaise—Epirubicin—liver cancer	0.00162	0.00241	CcSEcCtD
Flecainide—Nervousness—Doxorubicin—liver cancer	0.00161	0.0024	CcSEcCtD
Flecainide—Vertigo—Epirubicin—liver cancer	0.00161	0.0024	CcSEcCtD
Flecainide—Syncope—Epirubicin—liver cancer	0.00161	0.00239	CcSEcCtD
Flecainide—Leukopenia—Epirubicin—liver cancer	0.00161	0.00239	CcSEcCtD
Flecainide—Palpitations—Epirubicin—liver cancer	0.00159	0.00236	CcSEcCtD
Flecainide—Loss of consciousness—Epirubicin—liver cancer	0.00158	0.00234	CcSEcCtD
Flecainide—Cough—Epirubicin—liver cancer	0.00157	0.00233	CcSEcCtD
Flecainide—Vision blurred—Doxorubicin—liver cancer	0.00157	0.00233	CcSEcCtD
Flecainide—Convulsion—Epirubicin—liver cancer	0.00156	0.00231	CcSEcCtD
Flecainide—Hypertension—Epirubicin—liver cancer	0.00155	0.0023	CcSEcCtD
Flecainide—Ill-defined disorder—Doxorubicin—liver cancer	0.00154	0.00229	CcSEcCtD
Flecainide—Arthralgia—Epirubicin—liver cancer	0.00153	0.00227	CcSEcCtD
Flecainide—Chest pain—Epirubicin—liver cancer	0.00153	0.00227	CcSEcCtD
Flecainide—Myalgia—Epirubicin—liver cancer	0.00153	0.00227	CcSEcCtD
Flecainide—Anxiety—Epirubicin—liver cancer	0.00152	0.00226	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00152	0.00226	CcSEcCtD
Flecainide—Discomfort—Epirubicin—liver cancer	0.00151	0.00224	CcSEcCtD
Flecainide—Malaise—Doxorubicin—liver cancer	0.0015	0.00223	CcSEcCtD
Flecainide—Dry mouth—Epirubicin—liver cancer	0.0015	0.00222	CcSEcCtD
Flecainide—Vertigo—Doxorubicin—liver cancer	0.00149	0.00222	CcSEcCtD
Flecainide—Syncope—Doxorubicin—liver cancer	0.00149	0.00221	CcSEcCtD
Flecainide—Leukopenia—Doxorubicin—liver cancer	0.00149	0.00221	CcSEcCtD
Flecainide—Confusional state—Epirubicin—liver cancer	0.00148	0.0022	CcSEcCtD
Flecainide—Palpitations—Doxorubicin—liver cancer	0.00147	0.00218	CcSEcCtD
Flecainide—Oedema—Epirubicin—liver cancer	0.00147	0.00218	CcSEcCtD
Flecainide—Loss of consciousness—Doxorubicin—liver cancer	0.00146	0.00217	CcSEcCtD
Flecainide—Cough—Doxorubicin—liver cancer	0.00145	0.00215	CcSEcCtD
Flecainide—Shock—Epirubicin—liver cancer	0.00144	0.00214	CcSEcCtD
Flecainide—Convulsion—Doxorubicin—liver cancer	0.00144	0.00214	CcSEcCtD
Flecainide—Nervous system disorder—Epirubicin—liver cancer	0.00144	0.00213	CcSEcCtD
Flecainide—Thrombocytopenia—Epirubicin—liver cancer	0.00144	0.00213	CcSEcCtD
Flecainide—Hypertension—Doxorubicin—liver cancer	0.00144	0.00213	CcSEcCtD
Flecainide—Tachycardia—Epirubicin—liver cancer	0.00143	0.00212	CcSEcCtD
Flecainide—Skin disorder—Epirubicin—liver cancer	0.00142	0.00211	CcSEcCtD
Flecainide—Hyperhidrosis—Epirubicin—liver cancer	0.00142	0.0021	CcSEcCtD
Flecainide—Chest pain—Doxorubicin—liver cancer	0.00142	0.0021	CcSEcCtD
Flecainide—Myalgia—Doxorubicin—liver cancer	0.00142	0.0021	CcSEcCtD
Flecainide—Arthralgia—Doxorubicin—liver cancer	0.00142	0.0021	CcSEcCtD
Flecainide—Anxiety—Doxorubicin—liver cancer	0.00141	0.00209	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00141	0.00209	CcSEcCtD
Flecainide—Discomfort—Doxorubicin—liver cancer	0.0014	0.00208	CcSEcCtD
Flecainide—Anorexia—Epirubicin—liver cancer	0.0014	0.00208	CcSEcCtD
Flecainide—Dry mouth—Doxorubicin—liver cancer	0.00138	0.00206	CcSEcCtD
Flecainide—Hypotension—Epirubicin—liver cancer	0.00137	0.00203	CcSEcCtD
Flecainide—Confusional state—Doxorubicin—liver cancer	0.00137	0.00203	CcSEcCtD
Flecainide—Oedema—Doxorubicin—liver cancer	0.00136	0.00201	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00134	0.00198	CcSEcCtD
Flecainide—Shock—Doxorubicin—liver cancer	0.00133	0.00198	CcSEcCtD
Flecainide—Nervous system disorder—Doxorubicin—liver cancer	0.00133	0.00198	CcSEcCtD
Flecainide—Thrombocytopenia—Doxorubicin—liver cancer	0.00133	0.00197	CcSEcCtD
Flecainide—Insomnia—Epirubicin—liver cancer	0.00133	0.00197	CcSEcCtD
Flecainide—Tachycardia—Doxorubicin—liver cancer	0.00132	0.00197	CcSEcCtD
Flecainide—Skin disorder—Doxorubicin—liver cancer	0.00132	0.00196	CcSEcCtD
Flecainide—Paraesthesia—Epirubicin—liver cancer	0.00132	0.00195	CcSEcCtD
Flecainide—Hyperhidrosis—Doxorubicin—liver cancer	0.00131	0.00195	CcSEcCtD
Flecainide—Dyspnoea—Epirubicin—liver cancer	0.00131	0.00194	CcSEcCtD
Flecainide—Somnolence—Epirubicin—liver cancer	0.0013	0.00194	CcSEcCtD
Flecainide—Anorexia—Doxorubicin—liver cancer	0.00129	0.00192	CcSEcCtD
Flecainide—Dyspepsia—Epirubicin—liver cancer	0.00129	0.00192	CcSEcCtD
Flecainide—Decreased appetite—Epirubicin—liver cancer	0.00127	0.00189	CcSEcCtD
Flecainide—Hypotension—Doxorubicin—liver cancer	0.00127	0.00188	CcSEcCtD
Flecainide—Gastrointestinal disorder—Epirubicin—liver cancer	0.00127	0.00188	CcSEcCtD
Flecainide—Fatigue—Epirubicin—liver cancer	0.00126	0.00188	CcSEcCtD
Flecainide—Constipation—Epirubicin—liver cancer	0.00125	0.00186	CcSEcCtD
Flecainide—Pain—Epirubicin—liver cancer	0.00125	0.00186	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00124	0.00184	CcSEcCtD
Flecainide—Insomnia—Doxorubicin—liver cancer	0.00123	0.00182	CcSEcCtD
Flecainide—Paraesthesia—Doxorubicin—liver cancer	0.00122	0.00181	CcSEcCtD
Flecainide—Dyspnoea—Doxorubicin—liver cancer	0.00121	0.0018	CcSEcCtD
Flecainide—Feeling abnormal—Epirubicin—liver cancer	0.00121	0.00179	CcSEcCtD
Flecainide—Somnolence—Doxorubicin—liver cancer	0.00121	0.00179	CcSEcCtD
Flecainide—Gastrointestinal pain—Epirubicin—liver cancer	0.0012	0.00178	CcSEcCtD
Flecainide—Dyspepsia—Doxorubicin—liver cancer	0.00119	0.00177	CcSEcCtD
Flecainide—Decreased appetite—Doxorubicin—liver cancer	0.00118	0.00175	CcSEcCtD
Flecainide—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00117	0.00174	CcSEcCtD
Flecainide—Fatigue—Doxorubicin—liver cancer	0.00117	0.00174	CcSEcCtD
Flecainide—Urticaria—Epirubicin—liver cancer	0.00116	0.00173	CcSEcCtD
Flecainide—Pain—Doxorubicin—liver cancer	0.00116	0.00172	CcSEcCtD
Flecainide—Constipation—Doxorubicin—liver cancer	0.00116	0.00172	CcSEcCtD
Flecainide—Body temperature increased—Epirubicin—liver cancer	0.00116	0.00172	CcSEcCtD
Flecainide—Abdominal pain—Epirubicin—liver cancer	0.00116	0.00172	CcSEcCtD
Flecainide—Feeling abnormal—Doxorubicin—liver cancer	0.00112	0.00166	CcSEcCtD
Flecainide—Gastrointestinal pain—Doxorubicin—liver cancer	0.00111	0.00165	CcSEcCtD
Flecainide—Urticaria—Doxorubicin—liver cancer	0.00108	0.0016	CcSEcCtD
Flecainide—Abdominal pain—Doxorubicin—liver cancer	0.00107	0.00159	CcSEcCtD
Flecainide—Body temperature increased—Doxorubicin—liver cancer	0.00107	0.00159	CcSEcCtD
Flecainide—Asthenia—Epirubicin—liver cancer	0.00105	0.00156	CcSEcCtD
Flecainide—Pruritus—Epirubicin—liver cancer	0.00104	0.00154	CcSEcCtD
Flecainide—Diarrhoea—Epirubicin—liver cancer	0.001	0.00149	CcSEcCtD
Flecainide—Asthenia—Doxorubicin—liver cancer	0.000973	0.00145	CcSEcCtD
Flecainide—Dizziness—Epirubicin—liver cancer	0.00097	0.00144	CcSEcCtD
Flecainide—Pruritus—Doxorubicin—liver cancer	0.00096	0.00143	CcSEcCtD
Flecainide—Vomiting—Epirubicin—liver cancer	0.000932	0.00138	CcSEcCtD
Flecainide—Diarrhoea—Doxorubicin—liver cancer	0.000928	0.00138	CcSEcCtD
Flecainide—Rash—Epirubicin—liver cancer	0.000925	0.00137	CcSEcCtD
Flecainide—Dermatitis—Epirubicin—liver cancer	0.000924	0.00137	CcSEcCtD
Flecainide—Headache—Epirubicin—liver cancer	0.000919	0.00136	CcSEcCtD
Flecainide—Dizziness—Doxorubicin—liver cancer	0.000897	0.00133	CcSEcCtD
Flecainide—Nausea—Epirubicin—liver cancer	0.000871	0.00129	CcSEcCtD
Flecainide—Vomiting—Doxorubicin—liver cancer	0.000863	0.00128	CcSEcCtD
Flecainide—Rash—Doxorubicin—liver cancer	0.000855	0.00127	CcSEcCtD
Flecainide—Dermatitis—Doxorubicin—liver cancer	0.000855	0.00127	CcSEcCtD
Flecainide—Headache—Doxorubicin—liver cancer	0.00085	0.00126	CcSEcCtD
Flecainide—Nausea—Doxorubicin—liver cancer	0.000806	0.0012	CcSEcCtD
Flecainide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—liver cancer	0.000726	0.0288	CbGpPWpGaD
Flecainide—CYP2D6—CYP2E1 reactions—CYP2E1—liver cancer	0.000619	0.0245	CbGpPWpGaD
Flecainide—CYP2C9—CYP2E1 reactions—CYP2E1—liver cancer	0.000613	0.0243	CbGpPWpGaD
Flecainide—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—liver cancer	0.000568	0.0225	CbGpPWpGaD
Flecainide—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—liver cancer	0.000517	0.0205	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—EFNB2—liver cancer	0.000501	0.0199	CbGpPWpGaD
Flecainide—CYP2C9—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.000471	0.0187	CbGpPWpGaD
Flecainide—CYP2D6—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	0.000458	0.0182	CbGpPWpGaD
Flecainide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.000456	0.0181	CbGpPWpGaD
Flecainide—SCN5A—Cardiac Progenitor Differentiation—IGF2—liver cancer	0.000453	0.018	CbGpPWpGaD
Flecainide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.000449	0.0178	CbGpPWpGaD
Flecainide—CYP2C9—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.00042	0.0166	CbGpPWpGaD
Flecainide—CYP2D6—Xenobiotics—CYP2E1—liver cancer	0.000383	0.0152	CbGpPWpGaD
Flecainide—CYP2C9—Xenobiotics—CYP2E1—liver cancer	0.00038	0.0151	CbGpPWpGaD
Flecainide—CYP2D6—Tamoxifen metabolism—CYP2E1—liver cancer	0.000369	0.0146	CbGpPWpGaD
Flecainide—CYP2C9—Tamoxifen metabolism—CYP2E1—liver cancer	0.000366	0.0145	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—EFNB2—liver cancer	0.000358	0.0142	CbGpPWpGaD
Flecainide—SCN5A—Cardiac Progenitor Differentiation—KDR—liver cancer	0.000345	0.0137	CbGpPWpGaD
Flecainide—SCN5A—Cardiac Progenitor Differentiation—MAPK14—liver cancer	0.000343	0.0136	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—EFNB2—liver cancer	0.00034	0.0135	CbGpPWpGaD
Flecainide—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	0.000329	0.0131	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—TRIO—liver cancer	0.0003	0.0119	CbGpPWpGaD
Flecainide—CYP2D6—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.000292	0.0116	CbGpPWpGaD
Flecainide—CYP2C9—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.00029	0.0115	CbGpPWpGaD
Flecainide—CYP2D6—Xenobiotics—CYP1A1—liver cancer	0.000276	0.0109	CbGpPWpGaD
Flecainide—CYP2C9—Xenobiotics—CYP1A1—liver cancer	0.000273	0.0108	CbGpPWpGaD
Flecainide—CYP2D6—Tamoxifen metabolism—CYP1A1—liver cancer	0.000265	0.0105	CbGpPWpGaD
Flecainide—CYP2C9—Tamoxifen metabolism—CYP1A1—liver cancer	0.000263	0.0104	CbGpPWpGaD
Flecainide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.000249	0.00986	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—EFNB2—liver cancer	0.000243	0.00961	CbGpPWpGaD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000237	0.00939	CbGpPWpGaD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000235	0.00931	CbGpPWpGaD
Flecainide—CYP2C9—Arachidonic acid metabolism—HPGDS—liver cancer	0.000224	0.00888	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—UGDH—liver cancer	0.000215	0.00854	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—TRIO—liver cancer	0.000214	0.0085	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—UGDH—liver cancer	0.000214	0.00847	CbGpPWpGaD
Flecainide—CYP2D6—Melatonin metabolism and effects—CYP1A1—liver cancer	0.000205	0.00811	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—TRIO—liver cancer	0.000204	0.00807	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—TCF4—liver cancer	0.000201	0.00799	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—HNF4A—liver cancer	0.000175	0.00693	CbGpPWpGaD
Flecainide—SCN5A—Cardiac Progenitor Differentiation—TGFB1—liver cancer	0.000174	0.00691	CbGpPWpGaD
Flecainide—CYP2C9—Arachidonic acid metabolism—GGT1—liver cancer	0.000168	0.00665	CbGpPWpGaD
Flecainide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000163	0.00648	CbGpPWpGaD
Flecainide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000159	0.00631	CbGpPWpGaD
Flecainide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000158	0.00626	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—ABL1—liver cancer	0.000158	0.00625	CbGpPWpGaD
Flecainide—CYP2D6—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000157	0.00623	CbGpPWpGaD
Flecainide—CYP2C9—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000156	0.00618	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—TRIO—liver cancer	0.000145	0.00576	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—TCF4—liver cancer	0.000137	0.00541	CbGpPWpGaD
Flecainide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000135	0.00535	CbGpPWpGaD
Flecainide—CYP2C9—Arachidonic acid metabolism—CYP1A1—liver cancer	0.000131	0.0052	CbGpPWpGaD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000129	0.00512	CbGpPWpGaD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000128	0.00507	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—NR1H4—liver cancer	0.000126	0.00499	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—NR1H4—liver cancer	0.000125	0.00495	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTA3—liver cancer	0.000124	0.00491	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTA3—liver cancer	0.000123	0.00486	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—GSTA3—liver cancer	0.000122	0.00484	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—GSTA3—liver cancer	0.000121	0.0048	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—KDR—liver cancer	0.00012	0.00474	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—HNF4A—liver cancer	0.000118	0.00469	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—MET—liver cancer	0.000117	0.00464	CbGpPWpGaD
Flecainide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000114	0.00453	CbGpPWpGaD
Flecainide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000113	0.0045	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTA4—liver cancer	0.000113	0.00449	CbGpPWpGaD
Flecainide—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000113	0.00448	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—ABL1—liver cancer	0.000113	0.00446	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTA4—liver cancer	0.000112	0.00445	CbGpPWpGaD
Flecainide—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000112	0.00444	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—GSTA4—liver cancer	0.000112	0.00442	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—GSTA4—liver cancer	0.000111	0.00439	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTA2—liver cancer	0.00011	0.00437	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTA2—liver cancer	0.000109	0.00433	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—ABL1—liver cancer	0.000107	0.00424	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTA1—liver cancer	0.000106	0.00422	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTA1—liver cancer	0.000105	0.00418	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—NAT2—liver cancer	0.000105	0.00417	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—NAT2—liver cancer	0.000104	0.00413	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—NAT2—liver cancer	0.000104	0.00411	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—NAT2—liver cancer	0.000103	0.00408	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—MMP2—liver cancer	9.76e-05	0.00387	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—CASP3—liver cancer	9.44e-05	0.00374	CbGpPWpGaD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	9.27e-05	0.00368	CbGpPWpGaD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	9.19e-05	0.00364	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—PPARA—liver cancer	9.18e-05	0.00364	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—JUN—liver cancer	9.17e-05	0.00364	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—CTNNB1—liver cancer	9.1e-05	0.00361	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—GPX3—liver cancer	8.82e-05	0.0035	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—GPX3—liver cancer	8.75e-05	0.00347	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—RAF1—liver cancer	8.64e-05	0.00343	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—KDR—liver cancer	8.53e-05	0.00338	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—MAPK14—liver cancer	8.48e-05	0.00336	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—HPGDS—liver cancer	8.41e-05	0.00333	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—MET—liver cancer	8.35e-05	0.00331	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—HPGDS—liver cancer	8.34e-05	0.00331	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—KDR—liver cancer	8.1e-05	0.00321	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—VEGFA—liver cancer	8.01e-05	0.00318	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—MET—liver cancer	7.93e-05	0.00314	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—EPT1—liver cancer	7.71e-05	0.00306	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—ABL1—liver cancer	7.63e-05	0.00303	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—PPARG—liver cancer	7.59e-05	0.00301	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—MMP9—liver cancer	7.34e-05	0.00291	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—MMP2—liver cancer	6.96e-05	0.00276	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—TNF—liver cancer	6.87e-05	0.00272	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—CYP2E1—liver cancer	6.86e-05	0.00272	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—CYP2E1—liver cancer	6.8e-05	0.00269	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—CYP2E1—liver cancer	6.76e-05	0.00268	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—CYP2E1—liver cancer	6.7e-05	0.00266	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—MMP2—liver cancer	6.62e-05	0.00262	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—VEGFA—liver cancer	6.59e-05	0.00261	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GGT1—liver cancer	6.3e-05	0.0025	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GGT1—liver cancer	6.24e-05	0.00247	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—PPARA—liver cancer	6.22e-05	0.00247	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—RAF1—liver cancer	6.17e-05	0.00245	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—RAF1—liver cancer	5.86e-05	0.00232	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—KDR—liver cancer	5.78e-05	0.00229	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—MAPK14—liver cancer	5.75e-05	0.00228	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—MET—liver cancer	5.66e-05	0.00224	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTP1—liver cancer	5.66e-05	0.00224	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTP1—liver cancer	5.61e-05	0.00222	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—KRAS—liver cancer	5.6e-05	0.00222	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—GSTP1—liver cancer	5.58e-05	0.00221	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—IL6—liver cancer	5.54e-05	0.0022	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—GSTP1—liver cancer	5.53e-05	0.00219	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—CTNNB1—liver cancer	5.34e-05	0.00212	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—MMP9—liver cancer	5.23e-05	0.00207	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTM1—liver cancer	5.2e-05	0.00206	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTM1—liver cancer	5.15e-05	0.00204	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—PPARG—liver cancer	5.14e-05	0.00204	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—GSTM1—liver cancer	5.13e-05	0.00203	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—GSTM1—liver cancer	5.08e-05	0.00201	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—MMP9—liver cancer	4.97e-05	0.00197	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	4.97e-05	0.00197	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—CYP1A1—liver cancer	4.93e-05	0.00195	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—CYP1A1—liver cancer	4.88e-05	0.00194	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—CYP1A1—liver cancer	4.86e-05	0.00193	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—CYP1A1—liver cancer	4.82e-05	0.00191	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	4.79e-05	0.0019	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—HRAS—liver cancer	4.76e-05	0.00189	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—MMP2—liver cancer	4.72e-05	0.00187	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—VEGFA—liver cancer	4.7e-05	0.00186	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—STAT3—liver cancer	4.65e-05	0.00184	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—IL6—liver cancer	4.56e-05	0.00181	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—VEGFA—liver cancer	4.47e-05	0.00177	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—TGFB1—liver cancer	4.31e-05	0.00171	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—RAF1—liver cancer	4.18e-05	0.00166	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—TNF—liver cancer	4.03e-05	0.0016	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—KRAS—liver cancer	4e-05	0.00158	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—KRAS—liver cancer	3.8e-05	0.0015	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—UGDH—liver cancer	3.68e-05	0.00146	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	3.66e-05	0.00145	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—UGDH—liver cancer	3.65e-05	0.00145	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—CTNNB1—liver cancer	3.62e-05	0.00143	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—MMP9—liver cancer	3.55e-05	0.00141	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—EPT1—liver cancer	3.46e-05	0.00137	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—EPT1—liver cancer	3.43e-05	0.00136	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—HRAS—liver cancer	3.4e-05	0.00135	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—TAT—liver cancer	3.28e-05	0.0013	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—TAT—liver cancer	3.26e-05	0.00129	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—IL6—liver cancer	3.25e-05	0.00129	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—HRAS—liver cancer	3.23e-05	0.00128	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	3.2e-05	0.00127	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—VEGFA—liver cancer	3.19e-05	0.00126	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—STAT3—liver cancer	3.15e-05	0.00125	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—IL6—liver cancer	3.09e-05	0.00122	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—AKT1—liver cancer	3e-05	0.00119	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—TGFB1—liver cancer	2.92e-05	0.00116	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—TNF—liver cancer	2.73e-05	0.00108	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—KRAS—liver cancer	2.71e-05	0.00107	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	2.4e-05	0.00095	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—HRAS—liver cancer	2.3e-05	0.000913	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CPT1B—liver cancer	2.23e-05	0.000885	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GLUL—liver cancer	2.23e-05	0.000885	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GLUL—liver cancer	2.21e-05	0.000877	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CPT1B—liver cancer	2.21e-05	0.000877	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—IL6—liver cancer	2.2e-05	0.000874	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—NR1H4—liver cancer	2.15e-05	0.000853	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—NR1H4—liver cancer	2.13e-05	0.000846	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTA3—liver cancer	2.12e-05	0.000839	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTA3—liver cancer	2.1e-05	0.000832	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—AKT1—liver cancer	2.03e-05	0.000806	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTA4—liver cancer	1.94e-05	0.000767	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTA4—liver cancer	1.92e-05	0.000761	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTA2—liver cancer	1.89e-05	0.000748	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.88e-05	0.000743	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTA2—liver cancer	1.87e-05	0.000741	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTA1—liver cancer	1.82e-05	0.000721	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTA1—liver cancer	1.8e-05	0.000715	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—NAT2—liver cancer	1.8e-05	0.000713	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—NAT2—liver cancer	1.78e-05	0.000707	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ALDOB—liver cancer	1.73e-05	0.000684	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.72e-05	0.00068	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ALDOB—liver cancer	1.71e-05	0.000678	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CRABP1—liver cancer	1.65e-05	0.000652	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CRABP1—liver cancer	1.63e-05	0.000647	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.47e-05	0.000582	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—HPGDS—liver cancer	1.44e-05	0.00057	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—HPGDS—liver cancer	1.43e-05	0.000565	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.42e-05	0.000562	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.29e-05	0.000512	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PSMA4—liver cancer	1.28e-05	0.000508	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PSMD10—liver cancer	1.28e-05	0.000508	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.27e-05	0.000505	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PSMA4—liver cancer	1.27e-05	0.000504	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PSMD10—liver cancer	1.27e-05	0.000504	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GOT2—liver cancer	1.25e-05	0.000494	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GOT2—liver cancer	1.24e-05	0.00049	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CYP2E1—liver cancer	1.17e-05	0.000465	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CYP2E1—liver cancer	1.16e-05	0.000461	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.13e-05	0.000446	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CYCS—liver cancer	1.1e-05	0.000435	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CYCS—liver cancer	1.09e-05	0.000431	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GOT1—liver cancer	1.08e-05	0.000427	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GGT1—liver cancer	1.08e-05	0.000427	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GGT1—liver cancer	1.07e-05	0.000423	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GOT1—liver cancer	1.07e-05	0.000423	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTP1—liver cancer	9.67e-06	0.000383	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTP1—liver cancer	9.59e-06	0.00038	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—HMOX1—liver cancer	9.54e-06	0.000378	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—HMOX1—liver cancer	9.46e-06	0.000375	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTM1—liver cancer	8.89e-06	0.000352	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTM1—liver cancer	8.81e-06	0.000349	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CYP1A1—liver cancer	8.43e-06	0.000334	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CYP1A1—liver cancer	8.35e-06	0.000331	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—MTHFR—liver cancer	7.85e-06	0.000311	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—MTHFR—liver cancer	7.79e-06	0.000309	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PPARA—liver cancer	7.71e-06	0.000305	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PPARA—liver cancer	7.64e-06	0.000303	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.86e-06	0.000272	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PIK3CG—liver cancer	6.6e-06	0.000262	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PIK3CG—liver cancer	6.54e-06	0.000259	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PPARG—liver cancer	6.37e-06	0.000252	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PPARG—liver cancer	6.31e-06	0.00025	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PIK3CD—liver cancer	5.8e-06	0.00023	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PIK3CD—liver cancer	5.75e-06	0.000228	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ALB—liver cancer	5.73e-06	0.000227	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ALB—liver cancer	5.68e-06	0.000225	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PIK3CB—liver cancer	5.06e-06	0.0002	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PIK3CB—liver cancer	5.01e-06	0.000199	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PIK3CA—liver cancer	3.08e-06	0.000122	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PIK3CA—liver cancer	3.06e-06	0.000121	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—AKT1—liver cancer	2.52e-06	9.98e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—AKT1—liver cancer	2.5e-06	9.9e-05	CbGpPWpGaD
